Evaluation of enrofloxacin use in koalas (Phascolarctos cinereus) via population pharmacokinetics and Monte Carlo simulation

Laura A Black, Cornelia Barbara Landersdorfer, Jurgen Bernd Bulitta, Joanna E Griffith, Merran Govendir

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)


Clinically normal koalas (n = 6) received a single dose of intravenous enrofloxacin (10 mg/kg). Serial plasma samples were collected over 24 h, and enrofloxacin concentrations were determined via high-performance liquid chromatography. Population pharmacokinetic modeling was performed in S-ADAPT. The probability of target attainment (PTA) was predicted via Monte Carlo simulations (MCS) using relevant target values (30-300) based on the unbound area under the curve over 24 h divided by the minimum inhibitory concentration (MIC) (fAUC0-24/MIC), and published subcutaneous data were incorporated (Griffith et al., 2010). A two-compartment disposition model with allometrically scaled clearances (exponent: 0.75) and volumes of distribution (exponent: 1.0) adequately described the disposition of enrofloxacin. For 5.4 kg koalas (average weight), point estimates for total clearance (SE ) were 2.58 L/h (15 ), central volume of distribution 0.249 L (14 ), and peripheral volume 2.77 L (20 ). MCS using a target fAUC0-24/MIC of 40 predicted highest treatable MICs of 0.0625 mg/L for intravenous dosing and 0.0313 mg/L for subcutaneous dosing of 10 mg/kg enrofloxacin every 24 h. Thus, the frequently used dosage of 10 mg/kg enrofloxacin every 24 h subcutaneously may be appropriate against gram-positive bacteria with MICs = 0.03 mg/L (PTA > 90 ), but appears inadequate against gram-negative bacteria and Chlamydiae in koalas.
Original languageEnglish
Pages (from-to)301 - 311
Number of pages11
JournalJournal of Veterinary Pharmacology and Therapeutics
Issue number3
Publication statusPublished - 2014

Cite this